Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on Tuesday clarifying the relationship between its scientific research activities and those of Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI, despite prior references to research publications that included Quantumzyme affiliations.
The clarification addresses disclosures made in press releases dated November 5, 2025, and February 12, 2026, which cited scientific publications in the broader field of enzyme engineering and biocatalysis. Those publications listed Quantumzyme LLP as the affiliation of contributing researchers, including Quantum Genesis AI’s Chief Executive Officer, Naveen Kulkarni. The company now seeks to distinguish the entity from its own operations and provide additional context regarding intellectual property transfers.
According to the statement, Kulkarni transferred certain intellectual property, know-how, methodologies, and related rights to Quantum Genesis AI under an Asset Purchase Agreement dated February 21, 2023. A subsequent confirmatory assignment, disclosed in a Form 8-K filed on April 29, 2026, further solidified the transfer of technology associated with the company’s enzyme engineering and biocatalysis platform.
“The Company believes that the Asset Purchase Agreement transferred certain underlying technology, methodologies, computational approaches, know-how, and related intellectual property associated with the Company’s business,” the press release stated. As a result, Quantum Genesis AI asserts that research activities conducted by Kulkarni, whether directly or through Quantumzyme LLP, that relate to the company’s core field and are derived from the transferred technology fall within the scope of rights transferred to the company.
The clarification comes amid growing interest in the company’s work at the intersection of artificial intelligence, computational modeling, and biotechnology. Quantum Genesis AI focuses on enzyme engineering, molecular modeling, and biocatalysis, leveraging advanced data-driven tools to support research and technology development.
Investors and industry observers may view this clarification as an effort to reinforce the company’s ownership of key intellectual property, which could have implications for its competitive position and future partnerships. The company’s prior disclosures regarding scientific publications were made based on its ownership of the relevant intellectual property, as stated in the release.
For more information, visit the company’s website at qgaicorp.com and its profile on OTC Markets.
